von Pawel, J., Spigel, D. R., Ervin, T., Losonczy, G., Barlesi, F., Juhász, E., . . . Reck, M. (2018). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer. The oncologist (Dayton, Ohio), 23(6), 654-e58. https://doi.org/10.1634/theoncologist.2017-0690
Chicago-Zitierstil (17. Ausg.)von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio) 23, no. 6 (2018): 654-e58. https://doi.org/10.1634/theoncologist.2017-0690.
MLA-Zitierstil (9. Ausg.)von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio), vol. 23, no. 6, 2018, pp. 654-e58, https://doi.org/10.1634/theoncologist.2017-0690.